Table 2.
9p24.1 Amplified Renal Cell Carcinomas: Clinicopathologic Features
| Case Identifier | Age | Gender | Renal Cell Carcinoma Subtype | Sarcomatoid/Rhabdoid Features | WHO Grade | Size (cm) | pT | N | M | Follow Up | Immunotherapy |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Case 1 (Discovery Cohort) | 58 | Male | Chromophobe | Sarcomatoid | NA | 15.5 | pT3a | N1 | Mx | disease (5 months) | None |
| Case 2 (Discovery Cohort) | 71 | Male | (Metastasis to brain) Renal cell carcinoma, not otherwise specified | Sarcomatoid | - | - | - | - | M1 | Alive with disease (2 | None |
| Case 3 (Discovery Cohort & Casuscelli et al) | 58 | Male | Chromophobe | Sarcomatoid | NA | 10.5 | pT4 | Nx | M1 | Alive with disease (1.5 months) | None |
| Case 4* (Discovery Cohort) | 48 | Male | Clear Cell | Sarcomatoid | 4 | 10.1 | pT4 | N1 | M0 | Alive with disease (27.7 months) | First line therapy with lenvatinib (discontinued for persistence of disease) & pembrolizumab (discontinued for immune nephritis), for 16 months |
| Case 5* (Discovery Cohort) | 61 | Male | Clear Cell | Sarcomatoid | 4 | 15 | pT4 | N1 | M1 | Dead of disease (26 months) | First line therapy with bevacizumab and atezolizumab, for 14 months |
| Case 6 (TCGA-BP-4983) | 67 | Female | Clear Cell | Rhabdoid | 4 | 6.3 | pT3a | Nx | M0 | Alive without disease (116.5 months) | None |
| None Case 7 (Validation Cohort) | 54 | Female | Clear Cell | Sarcomatoid | 4 | 20 | pT3b | N0 | M1 | Dead of disease (6 months) | None |
| Case 8 (Validation Cohort | 71 | Male | Clear Cell | Sarcomatoid | 4 | 9 | pT3b | N0 | M1 | Dead of disease (16 months) | None |
| Case 9 (Validation Cohort) | 77 | Female | Clear Cell | Sarcomatoid | 4 | 10 | pT3a | N1 | M0 | Dead of disease (8 months) | None |
| Case 10 (Validation Cohort) | 70 | Male | Clear Cell | Sarcomatoid | 4 | 10 | pT2a | N0 | M0 | Dead of other causes (181 months) | None |
| Case 11 (TCGA-CZ-5468 | 84 | Male | Clear Cell | Sarcomatoid | 4 | 8.3 | pT3b | Nx | M1 | Dead of disease (2 months) | Data not available |
| Case 12 (TCGA-B8-4143 | 66 | Female | Clear Cell | None | 3 | 10 | pT3a | N0 | M1 | Dead of disease (23 months) | Data not available |
| Case 13 (Casuscelli et al | 31 | Male | Chromophobe | None | - | - | pT1 | N0 | M0 | Alive without disease (27 months) | Data not available |
*
Cases treated with immunotherapy
TCGA: The Cancer Genome Atlas; WHO: World Health Organization